A Study of Yutiq Steroid Insert During Glaucoma Tube Implant Surgery
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This is a pilot study, which will include approximately five eyes of 5 patients. This study
proposes that a sustained release steroid insert (Yutiq)1 be implanted along with a glaucoma
drainage device (Ahmed Glaucoma Valve (AGV) Model FP7) when the patient is undergoing
glaucoma tube implant surgery or combined glaucoma tube implant and cataract surgery. The
primary aim of this study is to assess the safety and efficacy (controlling intraocular
pressure) of the Yutiq inserts to reduce post-operative scarring in surgical glaucoma
patients. It is expected that post-operative week 12 onwards there will be a clinically and
statistically significant lower IOP in the study eyes than eyes in a group undergoing the
same surgery without the Yutiq insert. The estimated duration of the present study is 3
years.